Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The emergence of untreatable strains of typhoid threatens a new global health emergency that requires urgent collective action, argue experts from Paediatrics and the Oxford Martin School in Clinical Infectious Diseases.

International neglect of typhoid outside rich countries threatens a new global health emergency © Shutterstock

Typhoid still affects at least 11 million people every year, with the real figure potentially as high as 18 million. On the eve of the rollout of a new typhoid conjugate vaccine (TCV), the researchers are calling for global health institutions to dedicate new resources to tackling typhoid, which they say has become a neglected disease of poorer countries following its elimination in many high-income countries. Rising antimicrobial resistance and the ongoing outbreak of extensively drug-resistant (XDR) typhoid in Pakistan should be a wake-up call to the international community, they say.

New vaccines offer hope for typhoid control, but one intervention alone will be insufficient for eliminating the disease. Analysing the past and present of typhoid control, the researchers – including historians, immunologists and social scientists – identify a range of actions key to the strategic elimination of typhoid globally.

Read more (University of Oxford website)

Similar stories

Oxford Bundibugyo ebolavirus vaccine candidate receives CEPI backing

The Coalition for Epidemic Preparedness Innovations (CEPI) has announced today that it will urgently accelerate the development of three investigational vaccines targeting the Bundibugyo ebolavirus that has caused a rapidly spreading epidemic in the Democratic Republic of the Congo (DRC) and neighbouring Uganda, including one being developed by the Oxford Vaccine Group at the University of Oxford.

Statement on vaccine efforts relating to the Bundibugyo Ebolavirus outbreak in the DRC

In response to the current Bundibugyo Ebolavirus outbreak in the Democratic Republic of the Congo, the Oxford Vaccine Group (OVG) is working urgently with Oxford’s own Clinical BioManufacturing Facility and the Serum Institute of India Pvt. Ltd. (SIIPL), to rapidly produce and scale doses of our ChAdOx-based monovalent Bundibugyo Ebolavirus candidate vaccine, ChAdOx1 BDBV.

University of Oxford and Serum Institute of India Agree Licence to Advance the Next-Generation Multi-Stage Malaria Vaccine Candidate Component R78C

The University of Oxford, through Oxford University Innovation (OUI), and the Serum Institute of India (SII), a Cyrus Poonawalla group company and the world’s largest vaccine manufacturer by volume, have entered into a licence agreement to support the development and manufacture of the new malaria vaccine candidate R78C, which has been developed by the Draper Lab in the Department of Paediatrics, and is based on two Plasmodium falciparum blood-stage antigens (RIPR and CyPRA), for use in clinical settings.

New clinical trials begin in Burkina Faso

Vaccinations have started at the Institut de Recherche en Sciences de la Santé – Clinical Research Unit of Nanoro (IRSS-URCN), Burkina Faso for two clinical trials to assess the blood-stage malaria vaccine candidates R78C and RH5.1 with Matrix-M (developed by the Draper Lab in the Department of Paediatrics), in combination with the R21/​Matrix-M vaccine, which targets the earlier liver-stage. The trials are sponsored by the University of Oxford (UOXF), UK, with the European Vaccine Initiative (EVI) acting as both a co-funder and collaborator. These exciting studies are expected to provide proof-of-concept for the use of a multi-stage vaccine to extend the protection against malaria and help lead to future efforts to eliminate it by targeting two stages of the parasite’s life-cycle.

World's first Phase II Nipah virus vaccine trial launch

The University of Oxford has launched the world’s first Phase II clinical trial of a Nipah virus vaccine candidate.

Global Consortium Launched to Develop Next-Generation Malaria Vaccine

A new international consortium has been established to advance the development of a next-generation malaria vaccine, that aims to extend the protection against malaria and help lead to future efforts to eliminate it by targeting multiple stages of the parasite’s life-cycle.

Similar stories

Oxford Bundibugyo ebolavirus vaccine candidate receives CEPI backing

The Coalition for Epidemic Preparedness Innovations (CEPI) has announced today that it will urgently accelerate the development of three investigational vaccines targeting the Bundibugyo ebolavirus that has caused a rapidly spreading epidemic in the Democratic Republic of the Congo (DRC) and neighbouring Uganda, including one being developed by the Oxford Vaccine Group at the University of Oxford.

Statement on vaccine efforts relating to the Bundibugyo Ebolavirus outbreak in the DRC

In response to the current Bundibugyo Ebolavirus outbreak in the Democratic Republic of the Congo, the Oxford Vaccine Group (OVG) is working urgently with Oxford’s own Clinical BioManufacturing Facility and the Serum Institute of India Pvt. Ltd. (SIIPL), to rapidly produce and scale doses of our ChAdOx-based monovalent Bundibugyo Ebolavirus candidate vaccine, ChAdOx1 BDBV.

University of Oxford and Serum Institute of India Agree Licence to Advance the Next-Generation Multi-Stage Malaria Vaccine Candidate Component R78C

The University of Oxford, through Oxford University Innovation (OUI), and the Serum Institute of India (SII), a Cyrus Poonawalla group company and the world’s largest vaccine manufacturer by volume, have entered into a licence agreement to support the development and manufacture of the new malaria vaccine candidate R78C, which has been developed by the Draper Lab in the Department of Paediatrics, and is based on two Plasmodium falciparum blood-stage antigens (RIPR and CyPRA), for use in clinical settings.

New clinical trials begin in Burkina Faso

Vaccinations have started at the Institut de Recherche en Sciences de la Santé – Clinical Research Unit of Nanoro (IRSS-URCN), Burkina Faso for two clinical trials to assess the blood-stage malaria vaccine candidates R78C and RH5.1 with Matrix-M (developed by the Draper Lab in the Department of Paediatrics), in combination with the R21/​Matrix-M vaccine, which targets the earlier liver-stage. The trials are sponsored by the University of Oxford (UOXF), UK, with the European Vaccine Initiative (EVI) acting as both a co-funder and collaborator. These exciting studies are expected to provide proof-of-concept for the use of a multi-stage vaccine to extend the protection against malaria and help lead to future efforts to eliminate it by targeting two stages of the parasite’s life-cycle.

World's first Phase II Nipah virus vaccine trial launch

The University of Oxford has launched the world’s first Phase II clinical trial of a Nipah virus vaccine candidate.

Global Consortium Launched to Develop Next-Generation Malaria Vaccine

A new international consortium has been established to advance the development of a next-generation malaria vaccine, that aims to extend the protection against malaria and help lead to future efforts to eliminate it by targeting multiple stages of the parasite’s life-cycle.